The objective of this proposed study is to obtain data on the efficacy of Botox in reducing
symptoms of MDD in male and female patients between the ages of 18 and 65 years old.
The secondary object is to visually assess each patient's frown before and after the Botox
injection to determine if there is a correlation between changes in the frown and changes in
mood. The patients will be photographed at screening, visit 2 and 3. Their frown lines will
be compared to determine if there is a visible improvement in the frown lines corresponding
to an improvement in the efficacy rating scores.
Phase:
Phase 4
Details
Lead Sponsor:
Capital Clinical Research Associates, LLC
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA Pharmaceutical Solutions